| Patients (n) | Median Follow-Up (mo) | Recurrence (%) |
Local Recurrence (%) |
Bladder Recurrence (%) | Distant Metas-tasis (%) | Overall Survival (%) |
CancerSpecific Survival (%) |
Risk Factor Associated to Survival (%) | |
|---|---|---|---|---|---|---|---|---|---|
| LNU X Series | |||||||||
| El Fettouh (2002) [17] | 116 | 25 | Not stated | Not stated | 24 | 9 | Not stated | 87 (2 year) | Not stated |
| Muntener (2007) [18] | 39 | 74 | 46 | 5 | Not stated | 18 | 59 (5 year) | 68 (5 year) | Tumor stage |
| LNU X Open Surgery | |||||||||
| Bariol (2004) [19] |
58 26/22 |
101/96 | Not stated | 8/15 | 28/42 | 28/18 | 56/9 | 72/82 (5 year) | Not stated |
| Roupret (2006) [20] |
46 20/26 |
68/78 | 19 (urothelial) | Not stated | Not stated | 10/35 | Not stated | 90/61 (5 year) | Tumor stage and grade |
| Manabe (2007) [22] |
224 58/166 |
14/28 (mean) | 33/38 | 1 case port/2 cases | Not stated | 17/20 | 84/84 (2 year) | 85/82 (2 year) | Tumor stage and grade |